ReviewAnnals of medicine and surgery (2012)2025
A narrative review on the lactic acidosis and hypoglycemia in burkitt lymphoma: navigating metabolic changes.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma closely associated with Epstein-Barr virus (EBV) infection and driven by MYC oncogene overexpression. It presents in three clinical forms: endemic, sporadic, and immunodeficiency-associated. Endemic Burkitt lymphoma, prevalent in Africa, typically involves jaw tumors; sporadic cases commonly present with abdominal masses; and immunodeficiency-associated cases occur in patients with HIV or other forms of immune compromise. A major clinical challenge is the development of severe metabolic complications, including lactic acidosis and hypoglycemia, resulting from rapid tumor proliferation and increased metabolic demands, particularly through enhanced glycolysis (the Warburg effect). These complications are often resistant to conventional supportive therapies and become life-threatening without urgent intervention. Purpose: To emphasize the clinical significance of early recognition and management of metabolic complications in Burkitt lymphoma and to examine the role of chemotherapy, particularly rituximab-based regimens, in improving patient outcomes. Methods: We conducted a comprehensive literature search across PubMed, Cochrane Library, and Google Scholar databases through September 2024 using keywords related to rituximab complications in Burkitt lymphoma. Studies were screened according to predefined criteria, focusing on lactic acidosis and hypoglycemia. Only English-language clinical trials, randomized controlled trials, and reviews were included. We excluded articles that did not include Burkitt lymphoma patients or address associated metabolic challenges and treatment-related toxicities. Conclusion: Early diagnosis and prompt chemotherapy initiation are critical for managing tumor burden and associated metabolic derangements in Burkitt lymphoma. While rituximab has significantly improved treatment outcomes, it must be used judiciously to minimize severe adverse effects. Timely intervention is particularly crucial in immunocompromised patients, where disease progression and treatment toxicity may be more severe.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.